Event: Community Involvement in TB Drug Development: A roundtable discussion

23 May 2010
by Working Group

A Satellite Session at the 2nd TB Conference
June 3, 2010; 16:00 – 18:00
MR 11, ICC, Durban

Community engagement in TB drug research is growing practice, made possible by the fact that several new drug candidates are entering clinical trials. This roundtable will provide a forum for dialogue between researchers, community members, CBOs/NGOs, and advocates about methods for effective community engagement in TB research. Panelists representing several viewpoints will highlight successful practices for encouraging stakeholder involvement in research and discuss how communities can influence national policies and procedures to ensure the rapid adoption and roll-out of new TB regimens, once available.

Javid Syed, Treatment Action Group

Panel Presentations:

  • Research Literacy: A fundamental component of community engagement — Paula Akugizibwe, AIDS Rights Alliance South Africa (invited)
  • Community Outreach: A researcher’s perspective — Dr. Gavin Churchyard, Aurum Institute
  • Best Practices for Community Engagement in TB Drug Research — Dr. Jane Ong’ang’o, Kenya Medical Research Institute
  • Working with Local Government — Doctor Nuglube, Lusaka University Teaching Hospital Community Advisory Board
  • Advocacy for Policy Change — Nathan Geffen, Treatment Action Campaign

Panel presentations will be followed by open discussion. Light refreshments will be provided.

To indicate your interest in attending, please email

TB Alliance
Sponsored by the TB Alliance

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...